Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 121 to 130 of 1090 total matches.
Comparison Table: Some Drugs for Maintenance Treatment of Opioid Use Disorder (online only)
The Medical Letter on Drugs and Therapeutics • Sep 04, 2023 (Issue 1684)
Formulations
Target Maintenance
Dosage Adverse Effects Drug Interactions Pregnancy/Lactation Comments Cost1 ...
View Comparison Table: Some Drugs for Maintenance Treatment of Opioid Use Disorder
Med Lett Drugs Ther. 2023 Sep 4;65(1684):e144-5 doi:10.58347/tml.2023.1684b | Show Introduction Hide Introduction
Three New Drugs for Hyperlipidemia
The Medical Letter on Drugs and Therapeutics • Mar 03, 2003 (Issue 1151)
Three New Drugs for Hyperlipidemia ...
The FDA recently approved three new drugs for treatment of hyperlipidemia. Ezetimibe (ez et' i mibe; Zetia) is the first in a new class of drugs that inhibit intestinal absorption of cholesterol. Extended-release lovastatin (Altocor) is a new formulation of lovastatin (Mevacor, and others). Extended-release niacin plus (immediate-release) lovastatin (Advicor) is the first fixed-dose combination of lipid-lowering drugs.
Antibacterial Drugs for Community-Acquired Pneumonia
The Medical Letter on Drugs and Therapeutics • Jan 25, 2021 (Issue 1616)
and
torsades de pointes.8
DRUG INTERACTIONS — Coadministration of antacids
or products containing calcium ...
Treatment of community-acquired pneumonia (CAP)
is usually empiric, with selected antibiotic regimens
directed against some of the most common causative
pathogens. Recommended empiric regimens are
listed in Table 2; recommended antibiotic dosages for
treatment of CAP are listed in Tables 3 and 4. Joint
guidelines for treatment of CAP by the American
Thoracic Society and the Infectious Diseases Society of
America (ATS/IDSA) were updated in 2019.
Three New Drugs for Multiple Myeloma (online only)
The Medical Letter on Drugs and Therapeutics • May 23, 2016 (Issue 1495)
% and 7%) and
neutropenia (18% and 5%), and grade 3 anemia (9%).
Drug Interactions – Coadministration ...
The FDA recently approved ixazomib (Ninlaro –
Takeda), daratumumab (Darzalex – Janssen Biotech),
and elotuzumab (Empliciti – BMS) for treatment of
relapsed and/or refractory multiple myeloma.
Trelegy Ellipta - A Three-Drug Inhaler for COPD
The Medical Letter on Drugs and Therapeutics • May 21, 2018 (Issue 1547)
to lactating rats,
measurable drug levels were detected in some pups.
DRUG INTERACTIONS — Fluticasone furoate ...
The FDA has approved Trelegy Ellipta (GSK), a fixed-dose
combination of the inhaled corticosteroid (ICS)
fluticasone furoate, the long-acting antimuscarinic
agent (LAMA) umeclidinium, and the long-acting
beta2-agonist (LABA) vilanterol. It is available as a dry
powder inhaler for once-daily maintenance treatment
of COPD and to reduce COPD exacerbations in patients
with a history of exacerbations. Trelegy Ellipta is
the first three-drug inhaler for treatment of COPD to
become available in the US.
Drugs for Parasitic Infections
Treatment Guidelines from The Medical Letter • Aug 01, 2013 (Issue 143)
Drugs for Parasitic Infections ...
With increasing travel, immigration, use of immunosuppressive drugs and the spread of AIDS, physicians
anywhere may see infections caused by parasites. The table in this document lists first-choice and alternative drugs for most
parasitic infections.
Comparison Chart: Antiviral Drugs for Influenza for 2023-2024 (online only)
The Medical Letter on Drugs and Therapeutics • Nov 13, 2023 (Issue 1689)
within 10 hours after reconstitution
DRUG INTERACTIONS
DURATION OF THERAPY
TREATMENT:
Oseltamivir ...
View the Comparison Chart: Antiviral Drugs for Influenza for 2023-2024
Med Lett Drugs Ther. 2023 Nov 13;65(1689):e1-6 doi:10.58347/tml.2023.1689e | Show Introduction Hide Introduction
Antiviral Drugs for Influenza for 2023-2024
The Medical Letter on Drugs and Therapeutics • Nov 13, 2023 (Issue 1689)
or recombinant age-appropriate influenza vaccine.47
DRUG INTERACTIONS — Coadministration of
dairy products ...
Influenza is generally a self-limited illness, but
pneumonia, respiratory failure, and death can
occur, especially in patients at increased risk for
influenza complications (see Table 1). Antiviral drugs
recommended for treatment and chemoprophylaxis
of influenza for the 2023-2024 season are listed in
Table 2. Updated information on influenza activity
and antiviral resistance is available from the CDC at
www.cdc.gov/flu.
Med Lett Drugs Ther. 2023 Nov 13;65(1689):177-82 doi:10.58347/tml.2023.1689a | Show Introduction Hide Introduction
Two Drugs for Advanced HER2-Positive Breast Cancer (Enhertu and Tukysa)
The Medical Letter on Drugs and Therapeutics • Nov 16, 2020 (Issue 1611)
Two Drugs for Advanced HER2-Positive Breast Cancer (Enhertu and Tukysa) ...
The FDA has approved two new drugs for treatment
of previously-treated unresectable or metastatic
human epidermal growth factor receptor 2 (HER2)-positive breast cancer: fam-trastuzumab deruxtecannxki
(Enhertu – Daiichi-Sankyo/AstraZeneca), an IV
HER2-directed monoclonal antibody linked to the
topoisomerase I inhibitor DXd, and tucatinib (Tukysa – Seagen), an oral tyrosine kinase inhibitor.
Eliglustat (Cerdelga) - An Oral Drug for Gaucher Disease (online only)
The Medical Letter on Drugs and Therapeutics • Jul 06, 2015 (Issue 1472)
INTERACTIONS — Eliglustat is a substrate
of CYP2D6 and CYP3A4. Because high serum concentrations
of the drug ...
The FDA has approved eliglustat (Cerdelga –
Genzyme), an oral glucosylceramide synthase inhibitor,
for treatment of adults with type 1 Gaucher disease.
Eliglustat is metabolized primarily by CYP2D6. Because
patients who are CYP2D6 ultra-rapid metabolizers may
not achieve therapeutic concentrations and a specific
dosage cannot be recommended for indeterminate
metabolizers, the FDA has approved the drug only
for patients who are extensive, intermediate, or poor
metabolizers of CYP2D6.